HALIFAX, Feb. 17 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through
diagnostic technology, announced today that it has completed a second shipment
of its Over-The-Counter (OTC) MiraCare(TM) Rapid HIV Test (MiraCare(TM))
against a standing order. Since MiraCare's(TM) introduction, the number of
retail pharmacies selling the test has increased from 50 to over 300. This
second shipment comes just three weeks following the launch of this product
into Hong Kong and Macao, China announced on January 24, 2005. MiraCare(TM) is
distributed to pharmacies in Hong Kong and Macao by Goodman Medical Supplies
Ltd., a well-established medical supply distributor in this region, and is the
first in MedMira's new line of products destined for OTC purchase.
"As with all new products, introductory sales volumes have not yet
reached mass-market levels, but the consumer and retailer response to our OTC
rapid HIV test has been tremendous", said Hermes Chan, president and chief
operating officer of MedMira. "Feedback from the retail pharmacies has been
very positive, and we are encouraged by the acceptance of the general public
for a rapid OTC test for HIV." Chan continued, "Goodman's 40 years of
marketing experience and strong pharmacy networks in these regions, together
with our proven technology, is an invaluable combination".
MiraCare(TM) is sold as a complete test package with all components
required for an individual to conduct the test quickly; with results showing
in just three minutes.
MedMira is the leading global manufacturer and marketer of in vitro
flow-though rapid diagnostic tests for the clinical laboratory market.
MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the
detection of human antibodies in human serum, plasma or whole blood for
diseases such as HIV. The United States FDA and the SFDA in the People's
Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid
HIV Tests, respectively. For more information visit MedMira's website at
MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently
used in clinical laboratories and hospitals where professional counseling and
patient treatment are immediately available.
MedMira markets its rapid tests worldwide in such countries as the United
States, Canada, South Africa and China. Its corporate offices and
manufacturing facilities are located in Halifax, Nova Scotia, Canada with a
representative office in Beijing, China.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.